Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval from the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%-0.064%, the generic version of Enstilar Foam, 0.005%-0.064%, of Leo Pharma AS.
According to IQVIA sales data for the 12 month period ending March 2022, the Enstilar Foam, 0.005%-0.064% market achieved annual sales of around $115.2 million.
Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA’s pending approval with the U.S. FDA.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
